<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular endothelial growth factor (VEGF) is a potent angiogenic <z:chebi fb="7" ids="16670">peptide</z:chebi> with biologic effects that include regulation of hematopoietic stem cell development, extracellular matrix remodeling, and inflammatory cytokine generation </plain></SENT>
<SENT sid="1" pm="."><plain>To delineate the potential role of VEGF in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), VEGF protein and receptor expression and its functional significance in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> bone marrow (BM) were evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>In BM clot sections from <z:mpath ids='MPATH_458'>normal</z:mpath> donors, low-intensity cytoplasmic VEGF expression was detected infrequently in isolated myeloid elements </plain></SENT>
<SENT sid="3" pm="."><plain>However, monocytoid precursors in <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) expressed VEGF in an intense cytoplasmic pattern with membranous co-expression of the Flt-1 or KDR receptors, or both </plain></SENT>
<SENT sid="4" pm="."><plain>In situ hybridization confirmed the presence of VEGF <z:chebi fb="2" ids="33699">mRNA</z:chebi> in the neoplastic monocytes </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes, intense co-expression of VEGF and one or both receptors was detected in myeloblasts and immature myeloid elements, whereas erythroid precursors and lymphoid cells lacked VEGF and receptor expression </plain></SENT>
<SENT sid="6" pm="."><plain>Foci of abnormal localized immature myeloid precursors (ALIP) co-expressed VEGF and Flt-1 receptor, suggesting autocrine cytokine interaction </plain></SENT>
<SENT sid="7" pm="."><plain>Antibody neutralization of VEGF inhibited colony-forming unit (CFU)-<z:hpo ids='HP_0001909'>leukemia</z:hpo> formation in 9 of 15 CMML and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t patient specimens, whereas VEGF stimulated <z:hpo ids='HP_0001909'>leukemia</z:hpo> colony formation in 12 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Neutralization of VEGF activity suppressed the generation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha and interleukin-1beta from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> BM-mononuclear cells and BM-stroma and promoted the formation of CFU-GEMM and burst-forming unit-erythroid in <z:chebi fb="0" ids="53448">methylcellulose</z:chebi> cultures </plain></SENT>
<SENT sid="9" pm="."><plain>These findings indicate that autocrine production of VEGF may contribute to <z:hpo ids='HP_0001909'>leukemia</z:hpo> progenitor self-renewal and inflammatory cytokine elaboration in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and thus provide a biologic rationale for ALIP and its adverse prognostic relevance in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>